1994
DOI: 10.1006/biol.1994.1037
|View full text |Cite
|
Sign up to set email alerts
|

Interlaboratory Validation of in vitro Serological Assay Systems to Assess the Potency of Tetanus Toxoid in Vaccines for Veterinary Use

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
0

Year Published

1995
1995
2012
2012

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 0 publications
0
13
0
Order By: Relevance
“…In addition to rabies vaccines, workshop participants agreed that a synergy among experts in human and veterinary tetanus vaccines could facilitate and expedite the development of a replacement potency test for both of these vaccine products. Currently, in the United States and the EU, the potency tests for human and veterinary vaccines consist of vaccination of guinea pigs and serological evaluation of antitetanus toxoid antibodies by an indirect ELISA [44] or a toxin-binding inhibition (ToBI) test [45,47]. Efforts to develop a replacement test for either human or veterinary tetanus vaccines are impeded by the facts that toxoid vaccines are not well characterized, and potential analytical tests, including physiochemical and immunochemical tests, require much greater data generation, characterization, and validation for in-process and final product characterization [120].…”
Section: Clostridium Spp Vaccinesmentioning
confidence: 99%
“…In addition to rabies vaccines, workshop participants agreed that a synergy among experts in human and veterinary tetanus vaccines could facilitate and expedite the development of a replacement potency test for both of these vaccine products. Currently, in the United States and the EU, the potency tests for human and veterinary vaccines consist of vaccination of guinea pigs and serological evaluation of antitetanus toxoid antibodies by an indirect ELISA [44] or a toxin-binding inhibition (ToBI) test [45,47]. Efforts to develop a replacement test for either human or veterinary tetanus vaccines are impeded by the facts that toxoid vaccines are not well characterized, and potential analytical tests, including physiochemical and immunochemical tests, require much greater data generation, characterization, and validation for in-process and final product characterization [120].…”
Section: Clostridium Spp Vaccinesmentioning
confidence: 99%
“…Table 1 gives an overview of these studies and their current status. In addition, one of the first successful validation studies in the field of biologicals, the validation of an ELISA procedure and the toxin binding inhibition (ToBI) test for the batch potency testing of tetanus vaccines for veterinary use in 1992, was based on funds allocated by the European Commission for ECVAM (16). The use of an in vitro serological method (for example, the ToBI test) was incorporated for batch potency testing into the relevant monograph, and after calibration of the reference sera in an international collaborative study organised by the EDQM, biological reference preparations are now available (17), and the monograph will come into force in 2003.…”
Section: Prevalidation and Validation Studiesmentioning
confidence: 99%
“…ECVAM has contributed to several validation studies. In fact, one of the first successful studies, the validation of serological methods for the potency testing of tetanus vaccine for veterinary use, in 1992, was based on funding provided by the Commission for ECVAM (6). Furthermore, ECVAM has supported various other activities, such as the organisation of conferences and the evaluation of humane endpoints in vaccine potency testing.…”
Section: Ecvam's Activities In the Field Of Biologicalsmentioning
confidence: 99%
“…In 1992, a study began to validate the replacement of the TN test by three in vitro serological methods (6); an enzyme-linked immunosorbent assay (ELISA), the toxin binding inhibition (ToBI) test, and the haemagglutination (HA) test. The study was financed by the European Commission (formerly DG XI, now DG Environment).…”
Section: Tetanus Toxoid Vaccine For Veterinary Usementioning
confidence: 99%